Assembly Biosciences (ASMB) Net Cash Flow (2010 - 2026)

Assembly Biosciences' Net Cash Flow history runs 17 years deep, the most recent figure standing at -$27.3 million for Q1 2026.

• On a quarterly basis, Net Cash Flow fell 83.04% year-over-year to -$27.3 million in Q1 2026; TTM through Mar 2026 was $7.7 million, a 65.24% increase from a year earlier, with the FY2025 full-year figure at $20.1 million, up 8.66% from the prior year.
• Net Cash Flow declined to -$27.3 million in Q1 2026 per ASMB's latest filing, from $35.9 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $35.9 million in Q4 2025 and bottomed at -$27.3 million in Q1 2026.
• The 5-year median for Net Cash Flow is -$1.1 million (2024), against an average of -$853352.9.
• Biggest YoY gain for Net Cash Flow was 263.08% in 2025; the steepest drop was 1267.31% in 2025.
• Year by year, Net Cash Flow stood at -$2.3 million in 2022, then sank by 202.22% to -$6.8 million in 2023, then soared by 245.15% to $9.9 million in 2024, then soared by 263.08% to $35.9 million in 2025, then tumbled by 176.09% to -$27.3 million in 2026.
• Per Business Quant, the three latest ASMB Net Cash Flow figures stand at -$27.3 million (Q1 2026), $35.9 million (Q4 2025), and -$1.5 million (Q3 2025).